+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy

, : Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clinical Cancer Research 13(3): 1000-1009

The present study evaluated and compared the efficacy of pegvisomant and octreotide in blocking the growth hormone (GH) axis in humans based on pharmacodynamic biomarkers associated with the GH axis. The study also evaluated the safety of pegvisomant given at high s.c. doses for 14 days. Eighty healthy subjects were enrolled in five cohorts: cohorts 1 to 3, s.c. pegvisomant at 40, 60, or 80 mg once dailyx14 days (n=18 per cohort); cohort 4, s.c. octreotide at 200 microg thrice dailyx14 days (n=18); and cohort 5, untreated control (n=8). Serial blood samples were collected to measure plasma concentrations of total insulin-like growth factor type I (IGF-I), free IGF-I, IGF-II, IGF-binding protein 3 (IGFBP-3), and GH in all subjects and serum pegvisomant concentrations in subjects of cohorts 1 to 3. All subjects receiving treatment were monitored for adverse events (AE). After s.c. dosing of pegvisomant once daily for 14 days, the mean maximum suppression values of total IGF-I were 57%, 60%, and 62%, at 40, 60, and 80 mg dose levels, respectively. The maximum suppression was achieved approximately 7 days after the last dose and was sustained for approximately 21 days. Pegvisomant also led to a sustained reduction in free IGF-I, IGFBP-3, and IGF-II concentrations by up to 33%, 46%, and 35%, respectively, and an increase in GH levels. In comparison, octreotide resulted in a considerably weaker inhibition of total IGF-I and IGFBP-3 for a much shorter duration, and no inhibition of IGF-II. AEs in pegvisomant-treated subjects were generally either grade 1 or 2. The most frequent treatment-related AEs included injection site reactions, headache, and fatigue. Pegvisomant at well-tolerated s.c. doses was considerably more efficacious than octreotide in suppressing the GH axis, resulting in substantial and sustained inhibition of circulating IGF-I, IGF-II, and IGFBP-3 concentrations. These results provide evidence in favor of further testing the hypothesis that pegvisomant, through blocking the GH receptor-mediated signal transduction pathways, could be effective in treating tumors that may be GH, IGF-I, and/or IGF-II dependent, such as breast and colorectal cancer.


PMID: 17289896

DOI: 10.1158/1078-0432.CCR-06-1910

Other references

Hohmann, B., 1973: On Ricinus border values in oilseed residues. Kraftfutter 56 (11)) 562

Scher, H.; Herr, H.; Sternberg, C.; Fair, W.; Bosl, G.; Morse, M.; Sogani, P.; Watson, R.; Dershaw, D.; Reuter, V., 1989: Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. A series of 71 patients with muscle invasive bladder cancer received a median of 3 cycles (range 1-6) of methotrexate, vinblastine, Adriamycin and cisplatin (M-VAC). Efficacy assessed by transurethral resection alone showed that 48% of patients we...

Purohit, M.; Jamaluddin, 1995: Seed mycoflora of palas Taub during storage. Seed Research (New Delhi) 21(2): 126-127, 1993 ( )

Davie, S.R.; Rubie, N.D.; Hammes, B.S.; Carrano, C.J.; Kirk, M.L.; Basu, P., 2001: Geometric control of reduction potential in oxomolybdenum centers: implications to the serine coordination in DMSO reductase. Inorganic Chemistry 40(12): 2632-2633

Juhlin, R.; Sällström, J.F.; Stenkvist, B., 1974: Binding of fluorescein labelled concanavalin A to human bone marrow cells in leukaemias and lymphomas. Scandinavian Journal of Haematology 13(4): 281-286

Hill, A.; Waddell, I.D.; Hopwood, D.; Burchell, A., 1989: The microsomal glucose-6-phosphatase enzyme of human gall-bladder. Microsomes isolated from adult human gall-bladders have for the first time been shown to contain specific glucose-6-phosphatase activity. The gall-bladder glucose-6-phosphatase enzyme has the same molecular weight (36,500 daltons) and similar immu...

Burakovskiĭ, V.I.; Bokeriia, L.A., 1972: Hyperbaric oxygenation in cardiosurgery. Grudnaia Khirurgiia 14(4): 3-14

Iijima, C.; Kyo, T., 1989: Quinoxalines xxvi. reactions of 2 quinoxalinyl thiocyanate with nucleophiles. 2-Quinoxalinyl thiocyanate (1) possesses four electrophilic sites, i.e., 2-position, 3-position, sulfur and cyano carbon, to receive nucleophilic attack. Grignard reagents attacked preferentially the sulfur atom to give sulfides (8-12). These sulf...

Chang C.; Simmons D.T.; Martin M.A.; Mora P.T., 1979: Identification and partial characterization of new antigens from sv 40 transformed mouse cells. Two new species of antigens were detected in SV-40-transformed mouse cells, in addition to the large (94,000 daltons) and small (20,000 daltons) tumor antigens. These antigens were immunoprecipitated from cell extracts by using anti-T serum and no...

Ogawa, T.; Fujita, M., 1997: Smooth pursuit responses to a peripheral moving target in humans Facilitation in the pursuit eye velocity after the cat1. Experimental Brain Research 116(1): 83-96